

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **CHANGE OF CHIEF EXECUTIVE OFFICER**

The Board (the “**Board**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) hereby announces that, Mr. Yang Junmin has tendered his resignation as Chief Executive Officer (“**CEO**”) of the Company with effect from 30 December 2019; and Ms. Sun Li has been appointed as new CEO of the Company with effect from 30 December 2019.

### **RESIGNATION OF CEO**

Mr. Yang Junmin (“**Mr. Yang**”) has tendered his resignation as CEO of the Company with effect from 30 December 2019 due to personal family reasons.

Mr. Yang has confirmed that he has no any disagreement with the Board in relation to his resignation, and there is no other matter in relation to above resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Yang for his significant contributions to the Company during his tenure of service.

## APPOINTMENT OF NEW CEO

The Board has appointed Ms. Sun Li (“**Ms. Sun**”) as CEO of the Company replacing Mr. Yang with effect from 30 December 2019. Moreover, Ms. Sun is also the Chairman of the Board, an Executive Director, Chairman of the Nomination Committee, and a member of the Remuneration Committee of the Company since 20 August 2015.

The biographical details of Ms. Sun are set out below:

Ms. Sun, aged 46, graduated from the Economic and Trade Faculty of Central South University with a bachelor’s degree in Technological Economics in June 1995 and attained a master’s degree in management from the Management Business Administration Faculty of Central South University in June 1998. Ms. Sun was among the first batch of candidates obtaining the qualification of sponsor representatives from the Securities Association of China in 2004. Ms. Sun has engaged in investment banking for 15 years, with rich experience in filtering quality corporations, restructuring, counseling, initial public offering projects as well as mergers and acquisitions of listed companies. From August 1998 to April 2004, she successively acted as the business director, senior manager, and business manager of the investment banking headquarters of Dapeng Securities Co., Ltd. (大鵬證券有限責任公司). From May 2004 to August 2005, she served as the deputy general manager of the Shenzhen investment banking division of Centergate Securities Co., Ltd. (中關村證券股份有限公司). From September 2005 to March 2010, she successively served as the business director, internal auditor, member of GEM’s advisory committee of the investment banking headquarters of China Merchants Securities Co., Ltd. (招商證券股份有限公司). From April 2010 to April 2013, she served as the general manager and internal auditor of the mergers and acquisitions division of Minsheng Securities Co., Ltd. (民生證券有限責任公司). From May 2013 until now, she serves as the president, director and co-partner of Beijing Yingguxinye Investment Co., Ltd (北京盈谷信擘投資有限公司). From September 2014 until now, she is the founding member of Tianjin Teda “Wings of the Angel” Investor Club. From May 2015 until now, she is appointed as the supervisors of Shenzhen Xiangyong Investment Company Limited and Dongguan Lvye Fertilisers Company Limited. From December 2015 until now, she is appointed as a director of Beijing Yingguchuangrong Information Technology Co., Ltd. (北京盈谷創融信息科技股份有限公司). From August 2015 until now, Ms. Sun is appointed as an executive director and the Chairman of the Board of the Company. From September 2015 to February 2019, she was the CEO of the Company.

Save as disclosed above, as at the date of this announcement, Ms. Sun (i) does not hold any other position with the Company or other members of the Company; (ii) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) does not hold any position in public companies for the last three years, the securities of which are listed in Hong Kong or any other overseas securities markets, and does not have any other major appointments or professional qualifications.

As at the date of this announcement, Ms. Sun holds 300,000,000 shares in long position of the Company, representing 15.83% of total issued share capital. Out of these shares, 180,000,000 shares are held by Shenzhen Xiangyong Investment Company Limited (“**Xiangyong Investment**”) and 120,000,000 shares are held by Dongguan Lvye Fertilizers Company Limited (“**Lvye Fertilizers**”). Ms. Sun is the beneficial owner of Beijing Yingguxinye Investment Co., Ltd. (“**Yingguxinye**”) holding its 15% equity interest, while Yingguxinye holds 100% equity interest in Xiangyong Investment and Lvye Fertilizers, respectively. Apart from the above, Ms. Sun does not any other equity interest (as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) in the Company.

Upon her appointment as the CEO of the Company, the service agreement entered into between Ms. Li and the Company has commenced on 30 December 2019 and will expire on 29 December 2022, in which it will be submitted to the Board for renewal thereafter. Ms. Li is entitled to a remuneration of RMB530,000 per annum for her appointment as the Chairman of the Board, Executive Director and CEO of the Company. Ms. Li’s remuneration is determined with reference to her responsibilities and duties with the Company and current market condition.

## **DEVIATION FROM CORPORATE GOVERNANCE CODE**

Given Ms. Sun is serving as both the Chairman of the Board and CEO at present, it has deviated from Provision A.2.1 of Corporate Governance Code (“**Code**”). The Board, however, is of the view that it is the most suitable arrangement at this stage for Ms. Li to hold the two positions at the same time as it is in the best interest of the Company and will help to maintain the policy continuity and operating stability of the Company. The Company has been actively selecting candidates for the position of CEO through various channels so as to comply with the provision A.2.1 of the Code as early as possible, improve the transparency and independence of the corporate governance.

Save as disclosed above, there is no information in relation to Ms. Li or her appointment which is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of GEM Listing Rules of the Stock Exchange, and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

By order of the Board  
**Tianjin TEDA Biomedical Engineering Company Limited**  
**Sun Li**  
*Chairman*

Tianjin, the PRC  
30 December 2019

*As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Hao Zhihui and Mr. He Xin; the non-executive directors of the Company are Mr. Cao Aixin, Dr. Li Ximing and Ms. Gai Li; the independent non-executive directors of the Company are Mr. Li Xudong, Mr. Wang Yongkang and Ms. Gao Chun.*

*This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*